Screener
Indivior Pharmaceuticals, Inc. INDV Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease right of use assets, net | 22 | 26 |
| Goodwill and other intangible assets, net | 2 | 2 |
| Deferred tax assets | 296 | 323 |
| Other noncurrent assets | 26 | 27 |
| Total assets | $1,197 | $1,201 |
| Liabilities and stockholders' deficit | ||
| Current liabilities | ||
| Accrued rebates and product returns | $551 | $582 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Indivior Pharmaceuticals, Inc. (INDV) reported deferred tax assets and other non-current assets of $26M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets decreased by 33.3% year-over-year, from $39M to $26M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets has grown at a -13.4% compound annual growth rate (CAGR), from $36M to $27M.
Ask your AI about Indivior Pharmaceuticals, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude